Document is current
Any future updates will be listed below
-
Authors
Lilja, Johanna
Kaivola, Jasmin https://orcid.org/0000-0002-1437-1828
Conway, James R. W. https://orcid.org/0000-0003-3787-277X
Vuorio, Joni https://orcid.org/0000-0003-2404-4545
Parkkola, Hanna https://orcid.org/0000-0003-0934-6211
Roivas, Pekka
Dibus, Michal https://orcid.org/0000-0003-0234-1389
Chastney, Megan R. https://orcid.org/0000-0002-9866-2322
Varila, Taru
Jacquemet, Guillaume https://orcid.org/0000-0002-9286-920X
Peuhu, Emilia https://orcid.org/0000-0003-4945-3046
Wang, Emily
Pentikäinen, Ulla
Martinez D. Posada, Itziar
Hamidi, Hellyeh https://orcid.org/0000-0003-4841-8927
Najumudeen, Arafath K. https://orcid.org/0000-0002-3764-5721
Sansom, Owen J. https://orcid.org/0000-0001-9540-3010
Barsukov, Igor L. https://orcid.org/0000-0003-4406-9803
Abankwa, Daniel https://orcid.org/0000-0003-2769-0745
Vattulainen, Ilpo https://orcid.org/0000-0001-7408-3214
Salmi, Marko
Ivaska, Johanna https://orcid.org/0000-0002-6295-6556
- License Information
-
More Information
Article History
Received: 9 December 2022
Accepted: 3 September 2024
First Online: 12 September 2024
Competing interests
: The authors J.L. and J.I. declare that they have filed patent applications related to these findings (Therapy of Ras-Dependent Cancers, WO/2021/160937; Nanobodies specifically binding to SH3 and multiple ankyrin repeat domains 3 (SHANK3), WO/2023/021181). All other authors declare no competing interests.
